KIU Publications

Publications Archive

Explore research, reports, and scholarly works from the vibrant academic community at Kampala International University.

No matching results? Clear all filters to begin a fresh search.

An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis

Author: Emmanuel Ifeanyi Obeagu1*, Emmanuel Muhimbura2, Byamungu Pahari Kagenderezo3, Onyekachi Splendid Uwakwe1, Sarah Nakyeyune4 and Getrude Uzoma Obeagu1
Publisher: Journal of Biomedical Sciences
Published: 2023
Section: School of Allied Health Sciences

Abstract

Sickle cell disease has been described by many scholars as a chronic inflammatory
disease which is linked to many factors such as endothelial destruction,
increased synthesis of reactive oxygen specie, haemolysis, increased synthesis
of pro inflammatory cytokines among others. Inflammatory process play a major
function in the activation of acute painful vaso-occlusion crisis that forms the main
reason for the hospitalization of patients with sickle cell anaemia. Inflammatory
processes, are key components of several complications of the disease including
autosplenectomy, acute chest syndrome, pulmonary hypertension, leg ulcer,
nephropathy and stroke and also ultimately initiates painful vaso-occlusion
episodes that characterize Sickle Cell Disease. This study titled “Update on
Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia in Crises, aims
at finding out the recent updates on interferon gamma; a pro-inflammatory
cytokine that plays a central role in inflammation and auto-immunity, and CRP;
an acute phase protein used as a marker of inflammation in sickle cell anaemia
patients in crisis. A lot of search engines were consulted in the course of writing
this review such as scopus, Pubmed Central, Web of Science, Semantics, Google
Scholar, Researchgate, Academia Edu, etc. Previous studies have suggested that
levels of pro-inflammatory cytokines vary between steady-state and crisis states
in SCA patients, hypothesized to help monitor clinical progression of the disease.
. Newer therapies that target pathways downstream of the sickle are considered
better options. This knowledge may have implications for the development of new
treatments for sickle cell disease